Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.45 |
| ▸ | GABRD | O14764 | 3/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.45 |
| ▸ | GABRE | P78334 | 3/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.45 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.45 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351540 | 0.98 | GABRP (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3086351 | 0.96 | GABRP (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Nitric Acid SCHEMBL7049249 | 0.89 | GABRP (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9632787 | 0.88 | GABRP (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9630611 | 0.86 | GABRP (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29619789 | 0.85 | DHODH (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28965796 | 0.85 | DHODH (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9839363 | 0.84 | SMN1; SMN2 (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28983540 | 0.83 | CYP2C9 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30924884 | 0.83 | CYP2C9 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795439-B2 | saponifying a solution of pyridine-2,3-dicarboxylic acid ester with NaOH to form the sodium pyridine-2,3-dicarboxylate, reacting the solution with an oxidizing agent (H2O2, NaClO or NaBrO) to remove impurities, acidifying the solution with H2SO4 to produce pyridine-2,3-dicarboxylic acid herbicide | BASF AKTIENGESELLSCHAFT (DE) | 2010-09-14 | — | — | US | disclosed |
| US-20070185331-A1 | In-situ treatment of pyridine 2,3-dicarboxylic acid esters with an oxidizing agent | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-09 | — | — | US | disclosed |
| EP-1644333-A1 | IN-SITU TREATMENT OF PYRIDINE-2,3-DICARBOXYLIC ACID ESTERS WITH AN OXIDIZING AGENT | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005005391-A1 | IN-SITU TREATMENT OF PYRIDINE-2,3-DICARBOXYLIC ACID ESTERS WITH AN OXIDIZING AGENT | BASF AKTIENGESELLSCHAFT (DE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185331-A1 | In-situ treatment of pyridine 2,3-dicarboxylic acid esters with an oxidizing agent | HAO2, NOX4, IDH2 | GABRP 812/4885GABRD 741/4885GABRA1 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.